Gastric Carcinoma Clinical Trial
Official title:
A Phase I-II Study of Tesetaxel Plus Capecitabine and Cisplatin in Subjects With Advanced Gastric Cancer
Cisplatin, an intravenously administered platinum agent, in combination with an
intravenously administered taxane and capecitabine has been shown to improve time to disease
progression and overall survival in previously untreated patients with gastric cancer.
This study is being performed to evaluate an orally administered taxane (tesetaxel) in
combination with cisplatin and capecitabine in previously untreated patients with gastric
cancer.
Status | Recruiting |
Enrollment | 63 |
Est. completion date | January 2014 |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Primary Inclusion Criteria: - At least 20 years of age - Histologically or cytologically confirmed gastric carcinoma, including gastric or gastroesophageal-junction adenocarcinoma. - Measurable disease (revised RECIST) based on computed tomography, or nonmeasurable disease - Previously untreated, unresectable advanced (M0) or unresectable metastatic (M1) disease except for prior adjuvant (or neo-adjuvant) chemotherapy. - ECOG performance status 0 or 1 - At least 4 weeks and recovery from effects of prior major surgery - Adequate bone marrow, hepatic, and renal function Primary Exclusion Criteria: - Operable gastric or gastroesophageal-junction cancer - Known brain metastasis - Second cancer - Previous adjuvant or neo-adjuvant chemotherapy with capecitabine and cisplatin in combination. (Previous adjuvant or neo-adjuvant monotherapy with capecitabine or S-1 or therapy with S-1 and cisplatin in combination or 5-FU and cisplatin in combination is allowed.) - Uncontrolled diarrhea - Nausea or vomiting for at least 3 consecutive days within the 14 days prior to registration despite the administration of standard antiemetic therapy - Symptomatic peripheral neuropathy = Grade 2 - Malabsorption syndrome or other disease that significantly affects gastrointestinal function - Other uncontrolled systemic illness |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Yonsei Cancer Center, Yonsei University College of Medicine | Seoul |
Lead Sponsor | Collaborator |
---|---|
Genta Incorporated |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival rate (in Phase 2 portion of study) | 6 months from the date of first dose of study medication | No | |
Secondary | Recommended dose of tesetaxel for Phase 2 (in Phase 1 portion of study) | The dose of tesetaxel in mg/m2 will be determined for Phase 2 based on the occurrence of dose-limiting toxicities in Phase 1. | Up to 21 days after first dose of study medication | Yes |
Secondary | Response rate, as defined in revised RECIST (in Phase 2 portion of study) | Up to 12 months following the date of first dose of study medication | No | |
Secondary | Duration of response (in Phase 2 portion of study) | Up to 12 months following the date of first dose of study medication | No | |
Secondary | Rate of responses at least 3 months in duration (in Phase 2 portion of study) | Up to 12 months following the date of first dose of study medication | No | |
Secondary | Disease control rate, which is defined as the percentage of patients with a response of any duration or stable disease at least 6 weeks in duration (in Phase 2 portion of study) | Up to 12 months following the date of first dose of study medication | No | |
Secondary | Durable response rate, which is defined as the percentage of patients with a response at least 6 months in duration (in Phase 2 portion of study) | Up to 12 months following the date of first dose of study medication | No | |
Secondary | Progression-free survival (in Phase 2 portion of study) | Up to 12 months following the date of first dose of study medication | No | |
Secondary | Overall survival (in Phase 2 portion of study) | Up to 12 months following the date of first dose of study medication | No | |
Secondary | Percentage of patients with adverse events (in Phase 1 and Phase 2 portions) | Up to 30 days after the last dose of study medication | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04602026 -
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
|
N/A | |
Not yet recruiting |
NCT03599778 -
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT00256321 -
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
|
Phase 2 | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Recruiting |
NCT02617134 -
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
|
Phase 1/Phase 2 | |
Recruiting |
NCT02317471 -
Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03735511 -
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
|
||
Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|
||
Recruiting |
NCT05596188 -
Anxiety Before Non-cardiac Surgery in Adults
|
||
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT00639522 -
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
|
Phase 1 | |
Recruiting |
NCT05811546 -
Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma
|
||
Recruiting |
NCT05229809 -
Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer
|
Phase 4 | |
Recruiting |
NCT02409199 -
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00970138 -
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT06408220 -
Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer
|
N/A | |
Recruiting |
NCT04443036 -
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
|
N/A | |
Active, not recruiting |
NCT04505553 -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
|
Phase 2 | |
Recruiting |
NCT02839954 -
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
|
Phase 1/Phase 2 |